Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism
Open Access
- 1 May 1993
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 67 (5) , 945-952
- https://doi.org/10.1038/bjc.1993.175
Abstract
There is great concern over the long-term influence of oral contraceptives on the development of breast cancer in women. Oestrogens are known to stimulate the growth of human breast cancer cells, and this laboratory has previously reported (Jeng & Jordan, 1991) that the 19-norprogestin norethindrone could stimulate the proliferation of MCF-7 human breast cancer cells. We studied the influence of the 19-norprogestins norgestrel and gestodene compared to a 'non' 19-norprogestin medroxyprogesterone acetate (MPA) on MCF-7 cell proliferation. The 19-norprogestins stimulated proliferation at a concentration of 10(-8) M, while MPA could not stimulate proliferation at concentrations as great as 3 x 10(-6) M. The stimulatory activity of the 19-norprogestins could be blocked by the antioestrogen ICI 164,384, but not by the antiprogestin RU486. Transfection studies with the reporter plasmids containing an oestrogen response element or progesterone response element (vitERE-CAT, pS2ERE-CAT, and PRE15-CAT) were performed to determine the intracellular action of norgestrel and gestodene. The 19-norprogestins stimulated the vitERE-CAT activity maximally at 10(-6) M, and this stimulation was inhibited by the addition of ICI 164,384. MPA did not stimulate vitERE-CAT activity. A single base pair alteration in the palindromic sequence of vitERE (resulting in the pS2ERE) led to a dramatic decrease in CAT expression by the 19-norprogestins, suggesting that the progestin activity required specific response element base sequencing. PRE15-CAT activity was stimulated by norgestrel, gestodene and MPA at concentrations well below growth stimulatory activity. This stimulation could be blocked by RU486. These studies suggest that the 19-norprogestins norgestrel and gestodene stimulate MCF-7 breast cancer cell growth by activating the oestrogen receptor.Keywords
This publication has 52 references indexed in Scilit:
- The Significance of Bleeding Patterns in Norplant Implant UsersObstetrics & Gynecology, 1991
- The Selectivity of a New ProgestinActa Obstetricia et Gynecologica Scandinavica, 1990
- The Risk of Breast Cancer after Estrogen and Estrogen–Progestin ReplacementNew England Journal of Medicine, 1989
- Contrasting ability of antiestrogens to inhibit MCF-7 growth stimulated by estradiol or epidermal growth factorEuropean Journal of Cancer and Clinical Oncology, 1989
- Biology and mode of action of pure antioestrogensJournal of Steroid Biochemistry, 1988
- Oral-Contraceptive Use and the Risk of Breast CancerNew England Journal of Medicine, 1986
- Clinical Pharmacokinetics of Oral Contraceptive SteroidsClinical Pharmacokinetics, 1983
- Decreased Risk of Endometrial Cancer among Oral-Contraceptive UsersNew England Journal of Medicine, 1980
- Incidence of Endometrial Cancer in Relation to the Use of Oral ContraceptivesNew England Journal of Medicine, 1980
- A case control study of carcinoma of the ovary.Journal of Epidemiology and Community Health, 1977